Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - fibrinogen - pulver og solvens til injektions- /infusionsvæske, opløsning - 1,5 g

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemorrhagics - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - midler til dermatitis, undtagen kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

laboratoire francais du fractionnement et des biotechnologies - normalt immunoglobulin til intravenøs brug, humant - infusionsvæske, opløsning - 100 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - medicin for obstruktiv sygdomme, - fasenra er angivet som en tilføjelse om vedligeholdelse behandling hos voksne patienter med svær eosinofil astma, der ikke er tilstrækkeligt kontrolleret på trods af høje doser af inhalerede corticosteroider plus en langtidsvirkende β-agonister.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - antiparasitiske produkter, insekticider og repellenter - dogs; cats; ferrets - dogsfor hunde, der lider af, eller er i risiko fra, blandet parasitære infektioner:behandling og forebyggelse af loppeangreb (ctenocephalides felis),behandling af bidende lus (trichodectes canis),behandling af øre-mide angrebets (otodectes cynotis), sarcoptic mange (forårsaget af sarcoptes scabiei var. canis), demodicosis (forårsaget af demodex canis),forebyggelse af sygdom hjerteorm (l3 og l4-larver af dirofilaria immitis),behandling af cirkulerende microfilariae (dirofilaria immitis),behandling af kutane dirofilariosis (voksne stadier af dirofilaria repens)forebyggelse af kutan dirofilariosis (l3 larver af dirofilaria repens),reduktion af cirkulerende microfilariae (dirofilaria repens),forebyggelse af angiostrongylosis (l4-larver og umodne voksne af angiostrongylus vasorum),behandling af angiostrongylus vasorum og crenosoma vulpis,forebyggelse af spirocercosis (spirocerca lupi),behandling af eucoleus (syn. capillaria) boehmi (voksne),behandling af øjet orm thelazia callipaeda (voksne),behandling af infektioner med mave-nematoder (l4-larver, umodne og voksne af toxocara canis, ancylostoma caninum og uncinaria stenocephala, voksne af toxascaris leonina og trichuris vulpis). produktet kan bruges som en del af en behandlingsstrategi for loppe allergi dermatitis (fad). catsfor katte, der lider af, eller er i risiko fra, blandet parasitære infektioner:behandling og forebyggelse af loppeangreb (ctenocephalides felis),behandling af øre-mide angrebets (otodectes cynotis),behandling af notoedric sukkerærter (notoedres cati),behandling af lungworm eucoleus aerophilus (syn. capillaria aerophila) (voksne),forebyggelse af lungworm sygdom (l3/l4-larver af aelurostrongylus abstrusus),behandling af lungworm aelurostrongylus abstrusus (voksne),behandling af øjet orm thelazia callipaeda (voksne),forebyggelse af sygdom hjerteorm (l3 og l4-larver af dirofilaria immitis),behandling af infektioner med mave-nematoder (l4-larver, umodne og voksne af toxocara cati og ancylostoma tubaeforme). produktet kan bruges som en del af en behandlingsstrategi for loppe allergi dermatitis (fad). ferretsfor fritter, der lider af, eller er i risiko fra, blandet parasitære infektioner:behandling og forebyggelse af loppeangreb (ctenocephalides felis),forebyggelse af sygdom hjerteorm (l3 og l4-larver af dirofilaria immitis).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

intervet international b.v. - celleassocieret levende rekombinant kalkunherpesvirus (stamme hvt / ilt-138), der udtrykker glycoproteinerne gd og gi af infektiøs laryngotracheitis-virus - immunologicals for aves, live viral vacciner - kylling - til aktiv immunisering af en-dag-gamle kyllinger for at reducere dødeligheden, kliniske tegn og læsioner som følge af infektion med infektiøs laryngotracheitis (ilt) virus og mareks sygdom (md) virus.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ceva sante animale - dinotefuran, pyriproxyfen, permethrin - permethrin, kombinationer - hunde - behandling og forebyggelse af loppeangreb (ctenocephalides felis, og ctenocephalides canis). behandling og forebyggelse af kryds angreb (rhipicephalus sanguineus, dermacentor reticulatus, ixodes ricinus). forebyggelse for at bide fra sand flyver (phlebotomus perniciosus), myg (culex pipiens, aedes aegypti) og stabil flyver (stomoxys calcitrans). behandling af myg (aedes aegypti) og stabil flyve (stomoxys calcitrans) angreb.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemophilia a - antihemorrhagics - behandling og profylakse af blødning hos patienter med hæmofili a (medfødt faktor viii-mangel). dette præparat indeholder ikke von willebrand-faktor og er derfor ikke indiceret ved von willebrand ' s sygdom.